• Skip to main content
BC

biochimica clinica

en_US English
en_US English it_IT Italian
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

CONTRIBUTI SCIENTIFICI – Scientific Papers

Volume:

Biochimica Clinica 2020; 44(4) 359-366

Pubblicato on-line:

September 9, 2020

DOI:

10.19186/BC_2020.045

Scarica in PDF:

Polimorfismi dei geni KLK3, RASA1 e NAALADL2: rischio di cancro alla prostata, aggressività della neoplasia e livelli sierici dell’Antigene Prostatico-Specifico
Polymorphisms of KLK3, RASA1 and NAALADL2 genes: prostate cancer risk, aggressiveness of neoplasia and serum PSA levels

AUTORI

Dania Bozzato1, Carlo-Federico Zambon2, Andrea Padoan1, Michela Pelloso3, Ada Aita3, Stefania Moz1, Filippo Navaglia3, Tommaso Prayer Galetti4, Filiberto Zattoni4, Daniela Basso1, Mario Plebani1
1Dipartimento di Medicina e Dipartimento di Medicina di Laboratorio, Università di Padova, Italia
2Dipartimento di Scienze Biomediche e Dipartimento di Medicina di Laboratorio, Università di Padova, Italia
3Dipartimento di Medicina di Laboratorio, Università di Padova, Italia
4Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Università di Padova, Italia

ABSTRACT

Polymorphisms of KLK3, RASA1 and NAALADL2 genes: prostate cancer risk, aggressiveness of neoplasia and serum PSA levels

Background: prostate cancer (Pca) is the second most common cancer among men and the sixth leading cause of death due to cancer among men worldwide. We aimed to verify if serum PSA levels and PCa risk/aggressiveness are modulated by polymorphisms of KLK3, RASA1 and NAALADL2 genes.
Methods: 1058 men have been studied; they consecutively underwent prostate biopsy for clinical suspicion of PCa. PCa was histologically diagnosed in 401 and ruled out in 657 men. Gleason score in PCa patients was ≤6 in 261, 7 in 83 and >7 in the remaining 57 PCa. tPSA and f/tPSA levels were determined. Four polymorphisms were studied: rs35148638 (RASA1), rs78943174 (NAALADL2), rs2735839 and rs17632542 (KLK3).
Results: PCa diagnosis was significantly predicted by the KLK3 rs17632542 polymorphism (p<0.001), tPSA (p<0.001) and f/tPSA (p<0.001). Carriers of the KLK3 rs17632542C rare allele had a significantly higher risk of PCa (p<0.001) (OR 2.1, 95% CI 1.40-3.19). Gleason score >7 was associated with increased tPSA (p<0.001), decreased f/tPSA (p=0.003) and the KLK3 rs2735839 A rare allele (p= 0.004). In controls, tPSA was significantly lower in subjects bearing NAALADL2 rs78943174T rare allele (p=0.029). f/tPSA was higher in subjects with the KLK3 rs17632542C rare allele (p<0.001) and with the RASA1 rs35148638 C/C genotypes (p=0.009). In PCa subjects, tPSA was not associated with the polymorphisms studied.
Conclusions: KLK3 rs17632542 and rs2735839 polymorphisms were significantly associated with the risk and aggressiveness of PCa respectively. NAALADL2, KLK3 rs17632542 and RASA1 polymorphisms were correlated with tPSA and f/tPSA serum levels, suggesting a genetically-based PSA expected values in absence of tumor. These results suggest a potential role of these polymorphisms as biomarkers for PCa in association with the diagnostic and prognostic indexes currently recognized.

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967